Last year, the U.S. Senate Special Committee on Aging launched a bipartisan effort to expose the public health and national security risks America’s overreliance on foreign-made generic drugs poses to ...

— Adrian García, CEO of Saya Bio. MEXICO CITY, MEXICO, January 26, 2026 /EINPresswire.com/ — Saya Biologics (Saya Bio), a Mexican biopharmaceutical company ...

Oklahomans who purchased certain generic prescription drugs between 2009 and 2019 may be eligible for compensation after two pharmaceutical companies agreed to pay $17.85 million to settle allegations ...

ProPublica is a nonprofit newsroom that investigates abuses of power. Sign up to receive our biggest stories as soon as they’re published. Senators introduced legislation on Thursday that would ...

John Wilkerson is a Washington correspondent for STAT who writes about the politics of health care. He is also the author of the twice-weekly D.C. Diagnosis newsletter. Emory is the data editor at ...

New Jersey has joined 42 other states in suing global pharmaceutical company Novartis and its spin-off Sandoz for engaging in what they describe as “one of the most egregious examples of ...

“Congress… evidently viewed that prospect [of off-label, patented uses] as an acceptable cost of expedited competition with respect to lawful unpatented uses.” – U.S. Solicitor General On Friday, the ...

Richard L. Jackson is the founder and CEO of Jackson Healthcare, the parent company of USAntibiotics. The United States leads the world in pharmaceutical innovation. But it is less successful in ...

ProPublica is a nonprofit newsroom that investigates abuses of power. Sign up to receive our biggest stories as soon as they’re published. Join us Jan. 14 for a virtual discussion about our Rx ...

Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Andres Almiray, a serial open-source ...

Cuban said the high fees the FDA charges to approve generic drugs are a major barrier to manufacturing lower-priced generics in the United States, according to the report. Cuban said Cost Plus Drugs, ...

In 2026, Novo Nordisk’s patent on semaglutide will expire in several countries, including India and China. Generic-drug makers are poised to flood these markets with inexpensive products. Industry ...